The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 10 of the 26 sources its claims cite were checked for support.
Synaptic Vesicle 2A (SV2A) Positron Emission Tomography (PET) Imaging as a Marker of Therapeutic Response in a Mouse Model of Depression
Open accessAbstract
High Resolution Image Download MS PowerPoint Slide In this preclinical pilot study, we used [ 11 C]UCB-J PET imaging to monitor the synaptic modulation in depression and after fluoxetine. PET imaging was performed in a validated mouse model of depression/anxiety (CORT model), and the effect of 5-week treatment with fluoxetine was tested. Depression/anxiety phenotype and antidepressant action of fluoxetine were confirmed using the novelty-suppressed feeding test, previously validated in the CORT model. PET data showed significant decreases of volume of distribution ( V T ) of [ 11 C]UCB-J in most brain regions of CORT mice compared with controls after 5 weeks of fluoxetine, and a trend toward restoration of V T values to control levels was observed, although it reached significance only in the olfactory bulb. These preliminary data support the use of [ 11 C]UCB-J PET imaging and the CORT model to study the synaptic modulation of antidepressants. It provides excellent translational opportunities to study the relationship between synaptic plasticity and the clinical efficacy of antidepressants.
Overview
CoChat Summary
TL;DR
In a preclinical pilot study, [11C]UCB-J PET imaging was used to monitor synaptic SV2A modulation in the corticosterone (CORT) mouse model of depression/anxiety and after fluoxetine. CORT mice showed lower [11C]UCB-J volume of distribution (VT) in most brain regions, and 5-week fluoxetine treatment showed a trend toward restoration that reached significance only in the olfactory bulb.
Key findings
- The novelty-suppressed feeding test confirmed the CORT phenotype: CORT mice had increased feeding latency at 4 weeks (251 ± 130 s) versus controls (134 ± 56 s), remained stable at 9 weeks (307 ± 206 s), and fluoxetine reduced latency from 276 ± 93 s to 62 ± 36 s (p = 0.0012).
- [11C]UCB-J VT was significantly lower in whole brain and several regions of CORT mice versus controls, including cortex, basal forebrain and septum, olfactory bulb, striatum, and hippocampus (reported as from −32% in the olfactory bulb to 14% in the hippocampus; F(22,198) = 1715; p = 0.029).
- After fluoxetine, VT increased versus CORT mice in the olfactory bulb (+28%; p = 0.017), with a global trend toward restoration across brain regions.
- Brain and plasma AUCs of [11C]UCB-J were not significantly different between control and CORT mice, but were significantly increased in CORT+Fluox versus CORT (46% brain and 29% plasma increases; p < 0.05).
Methods
- Adult male C57BL/6JRj mice (9 weeks) received corticosterone (35 μg/mL in drinking water) for 4 weeks (CORT, n = 12) or vehicle (control, n = 9); a subset of 6 CORT mice then received fluoxetine (18 mg/(kg day)) for 6 weeks (CORT+Fluox, n = 6).
- Behavioral testing used the novelty-suppressed feeding test before and after fluoxetine (at 4 and 9 ± 1 weeks), and PET imaging was performed at 10 ± 1 weeks.
- [11C]UCB-J PET used a bolus injection of 7.6 ± 1.4 MBq followed by 90 min dynamic acquisition; brain VT was estimated with Logan plot analysis using an image-derived input function corrected for unmetabolized plasma radioligand. Statistical analysis used two-way repeated measures ANOVA with Dunnett’s posthoc test and Mantel–Cox tests for Kaplan–Meier curves.
Limitations
- The paper states this is a pilot study with many limitations, including inability to correlate [11C]UCB-J VT with novelty-suppressed feeding results, so synaptic remodeling cannot be assumed to reflect neurogenesis.
- The authors state future studies should include females because of higher depression prevalence in women and sex differences in the CORT model, and should study SSRIs in both naive and stressed animals.
- The authors note increased AUCIDIF of [11C]UCB-J in CORT+Fluox and suggest a possible contribution from fluoxetine-induced heart hypertrophy reported in rats; evident limitations include small group sizes (n = 6 per treatment subset) and male-only sampling.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 0 Not valid · 9 Not checked · 15 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“First, the drastic increase in feeding latency in CORT mice compared to control mice, which was reversed by fluoxetine, confirmed the previously reported validity of the model of MDD for preclinical research.19”
What the sources say
- Partly supportedcites [19] sourceExperimental — accuracy not yet measured
The Results section (p. n/a, 'A 4-week Corticosterone Treatment Induced Anxiety/Depression-Like Phenotype') does report an increase in latency to feed in corticosterone-treated mice (p < 0.01) 'as previously described', and the Discussion ('Behavioral Emotionality and PBMCs Isolation...') states that this approach 'augmented the translational validity of the CORT model', so the validity/reproducibility part is in our copy. However, the reversal of the feeding latency by fluoxetine is overstated: the same paper reports only 'a trend for a reduction of chronic corticosterone-induced increase in latency to feed' after chronic fluoxetine (Results, 'Effects of a 4-week Treatment with Fluoxetine...', p = 0.08 for the bar-chart comparison), with significant fluoxetine effects in the EPM and splash test instead. Our copy also frames the model as an 'anxiety/depression-like' phenotype in mice, not explicitly as a validated model of MDD. (LLM, conf=0.78)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In mice, exogenous exposure to corticosterone (the CORT model) is now well related to the emergence of depressive-like endophenotypes, with an impact on anxiety, learning, and memory.5”
What the sources say
- Partly supportedcites [5] sourceExperimental — accuracy not yet measured
The Introduction and Results describe chronic exogenous corticosterone producing anxiety- and depression-like changes in mice, and the Discussion concludes that it models an anxious and depressed-like state. The paper does not report an effect of corticosterone exposure on learning or memory; its mention of cognitive dysfunction concerns depressed patients, not the treated mice. Page numbers are unavailable in our copy. (LLM, conf=0.88)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The novelty-suppressed feeding test (NSF) is a well-validated paradigm for measuring anxiety/depression-like behaviors and estimating antidepressant efficacy in the CORT model.5”
What the sources say
- Supportedcites [5] source
The Methods (Behavioral testing) describe NSF as an established conflict test. The Results (Effects of a 3-week antidepressant treatment) show that corticosterone increased latency to feed and that chronic fluoxetine and imipramine reversed this change, supporting NSF’s use to assess anxiety/depression-like behavior and antidepressant effects in the CORT model. (LLM, conf=0.88)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“These results echo those obtained in human MDD using [11C]UCB-J, where global decreases in synaptic density have been observed only in a subset of patients with high symptom severity.13”
What the sources say
- Supportedcites [13] source
The Results (Group differences in synaptic density) report lower [11C]UCB-J VT in the high-severity group than in healthy controls, but no significant difference for the low-severity group. The same section describes the differences as global; Fig. 2 identifies every high-severity participant as having MDD, either alone or with PTSD. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, given the evidence from both clinical and preclinical literature, it is very likely that SSRIs induce different synaptic patterns in patients and healthy subjects,11,27”
What the sources say
- Partly supportedcites [11] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that SSRI effect sizes and temporal dynamics might differ in patients, but the trial studied healthy participants only. It does not establish that different synaptic patterns in patients and healthy people are very likely. (LLM, conf=0.87)
- Not checked yetcites [27] source
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
10 more claims
Create a free account to see all 32 claims and to verify the 16 references still open.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 9
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Proof-of-concept data demonstrate partial recovery after fluoxetine in a depression model, and early work suggests ketamine may normalize low-baseline SV2A signal, linking circuit plasticity to presynaptic stabilization [167,217,218].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [218]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a translational biomarker, SV2A PET is well-positioned to monitor antidepressant-induced synaptic restoration [215,216,217,218].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [218]
The cited source says what the claim attributes to it.
In the citing paper
“Proof-of-concept data demonstrate partial recovery after fluoxetine in a depression model, and early work suggests ketamine may normalize low-baseline SV2A signal, linking circuit plasticity to presynaptic stabilization [167,217,218].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [218]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Abstract
“After 5 weeks of fluoxetine, a trend toward restoration of VT values to control levels was observed, although it reached significance only in the olfactory bulb.”
§ Abstract
“a subset of 6 mice was subjected to fluoxetine (fluoxetine hydrochloride 160 mg/mL, 18 mg/(kg day); Anawa-Trading, Switzerland), added to the corticosterone/vehicle solution (CORT+Fluox, n = 6), for 6 weeks as previously described.15”
Citations
Cites
David, D. J., Samuels, B. A., Rainer, Q., Wang, J.-W., Marsteller, D., Mendez, I., Drew, M., Craig, D. A., Guiard, B. P., Guilloux, J.-P., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.04.017 · Cited by 1,267
Self-citationNeuroplasticity in cognitive and psychological mechanisms of depression: an integrative model
Price, R. B., & Duman, R. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0615-x · Cited by 739
Effects of Chronic Fluoxetine in Animal Models of Anxiety and Depression
Dulawa, S. C., Holick, K. A., Gundersen, B., & Hen, R. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300433 · Cited by 671
Self-citationSustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation
Moda-Sava, R. N., Murdock, M. H., Parekh, P. K., Fetcho, R. N., Huang, B. S., Huynh, T. N., Witztum, J., Shaver, D. C., Rosenthal, D. L., Alway, E. J., et al. (2019) · Science · doi:10.1126/science.aat8078 · Cited by 643
The Role of Neural Plasticity in Depression: From Hippocampus to Prefrontal Cortex
Liu, W., Ge, T., Leng, Y., Pan, Z., Fan, J., Yang, W., & Cui, R. (2017) · Neural Plasticity · doi:10.1155/2017/6871089 · Cited by 640
Lower synaptic density is associated with depression severity and network alterations
Holmes, S. E., Scheinost, D., Finnema, S. J., Naganawa, M., Davis, M. T., DellaGioia, N., Nabulsi, N., Matuskey, D., Angarita, G. A., Pietrzak, R. H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09562-7 · Cited by 484
Sex differences in anxiety and depression: circuits and mechanisms
Bangasser, D. A., & Cuarenta, A. (2021) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00513-0 · Cited by 479
Kraus, C., Castrén, E., Kasper, S., & Lanzenberger, R. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.03.007 · Cited by 471
Zhang, K., Wang, F., Zhai, M., He, M., Hu, Y., Feng, L., Li, Y., Yang, J., & Wu, C. (2023) · Theranostics · doi:10.7150/thno.81067 · Cited by 217
Siopi, E., Denizet, M., Gabellec, M.-M., de Chaumont, F., Olivo-Marin, J.-C., Guilloux, J.-P., Lledo, P.-M., & Lazarini, F. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2817-15.2016 · Cited by 111
Cited by
Champault, A., Leterrier, S., Bel, R., Knoertzer, J., Soyer, A., Goutal, S., Baati, R., François, S., Tournier, N., Bo, G. D., et al. (2025) · Toxicology · doi:10.1016/j.tox.2025.154327 · Cited by 4
Self-citationSynaptic density in the hippocampus of depressed patients: A quantitative electron microscopic study
Sebők-Tornai, A., Csabai, D., Szocsics, P., Gombás, P., Cobb, J. A., Mahajan, G., Stockmeier, C. A., & Czéh, B. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111661 · Cited by 2
“…there is experimental evidence that antidepressive treatment may influence synaptic plasticity and increase the number of synapses (Hajszan et al., 2005; Chen et al., 2010; Duman et al., 2016; Holmes et al., 2023; Johansen et al., 2023; Laroy et al., 2024; Corvo et al., 2025; Liao et al., 2025).”
Corvo, C., Goutal, S., Mendez-David, I., Leterrier, S., Caille, F., Saba, W., Colle, R., Corruble, E., Lebon, V., Bottlaender, M., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-025-03369-3 · Cited by 1
Self-citationAsch, R., Martin, N. H., García-Milian, R., Fowles, K., Dileone, R., Cai, Z., Liston, C. M., & Esterlis, I. (2025) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2025.09.021 · Cited by 2
Ma, J., Braun, A., Oskamp, A., Kricsfalussy-Hrabár, L., Hermes, N., Djakkani, S., Holz, U., Jakobs, S., Klein, S., Stüsgen, S., et al. (2026) · iScience · doi:10.1016/j.isci.2026.116676
Knudsen, C., Thomsen, M. B., Højgaard, K., Christiansen, S. L., Wiborg, O., Müller, H. K., Landau, A. M., & Elfving, B. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111572
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
Metadata
- Authors
- Corvo, C., Mendez-David, I., Goutal, S., Saba, W., Bottlaender, M., Caillé, F., Hen, R., Colle, R., Corruble, E., Tournier, N., Leroy, C., & David, D. J.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Université Paris-Saclay, Centre de recherche en Epidémiologie et Santé des Populations (CESP-Inserm), UMR 1018, Team Moods
- Department of Psychiatry
- Inserm (FR)
- Corresponding author
- Leroy, Claire
- ORCID
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2025-01-28
- Volume
- 8
- Issue
- 2
- Pages
- 339-345
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC11833719
- OpenAlex
- W4406906918
- Cited by
- 7
- References
- 28
- Citations by year
- 2026: 3 · 2025: 4
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- HAL (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-11-IDEX-0003, ANR-22-CE17-0015)
- Universit? Paris-Saclay
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- SV2A, [11C]UCB-J, positron emission tomography, depression, fluoxetine, antidepressant response, synaptic plasticity, olfactory bulb, volume of distribution, anxiety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.